Search

Your search keyword '"Choquet, S."' showing total 470 results
Start Over Author "Choquet, S."
470 results on '"Choquet, S."'

7. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)

Author

Ghesquieres, H., Chevrier, M., Laadhari, M., Chinot, O., Choquet, S., Moluçon-Chabrot, C., Beauchesne, P., Gressin, R., Morschhauser, F., Schmitt, A., Gyan, E., Hoang-Xuan, K., Nicolas-Virelizier, E., Cassoux, N., Touitou, V., Le Garff-Tavernier, M., Savignoni, A., Turbiez, I., Soumelis, V., Houillier, C., and Soussain, C.

Published
2019
Full Text
View/download PDF

9. Molecular and clinical diversity in primary central nervous system lymphoma

Author

Hernández-Verdin, I., Kirasic, E., Wienand, K., Mokhtari, K., Eimer, S., Loiseau, H., Rousseau, A., Paillassa, J., Ahle, G., Lerintiu, F., Uro-Coste, E., Oberic, L., Figarella-Branger, D., Chinot, O., Gauchotte, G., Taillandier, L., Marolleau, J.-P., Polivka, M., Adam, C., Ursu, R., Schmitt, A., Barillot, N., Nichelli, L., Lozano-Sánchez, F., Ibañez-Juliá, M.-J., Peyre, M., Mathon, B., Abada, Y., Charlotte, F., Davi, F., Stewart, C., de Reyniès, A., Choquet, S., Soussain, C., Houillier, C., Chapuy, B., Hoang-Xuan, K., Alentorn, A., Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), University Medical Center Göttingen (UMG), Freie Universität Berlin, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de pathologie [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, CHU Bordeaux [Bordeaux], Imagerie moléculaire et thérapies innovantes en oncologie (IMOTION), Université de Bordeaux (UB), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Service de Neurologie [Hôpitaux Civils de Colmar], Hôpitaux Civils Colmar, Hôpitaux Civils de Colmar, Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de la Timone [CHU - APHM] (TIMONE), Institut de neurophysiopathologie (INP), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CHU Amiens-Picardie, HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666 (HEMATIM), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Université Paris Diderot - Paris 7 (UPD7), Hopital Saint-Louis [AP-HP] (AP-HP), Institut Bergonié [Bordeaux], UNICANCER, Sorbonne Université (SU), Centre Hospitalier Saint Jean de Perpignan, Broad Institute of MIT and Harvard (BROAD INSTITUTE), Harvard Medical School [Boston] (HMS)-Massachusetts Institute of Technology (MIT)-Massachusetts General Hospital [Boston], Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Institut Curie - Saint Cloud (ICSC), DESSAIVRE, Louise, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d’Anatomie Pathologique [CHRU Nancy], and École pratique des hautes études (EPHE)

Subjects
[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Oncology, tumor heterogeneity, Hematology, multi-omics, microenvironment, PCNSL, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Primary central nervous system lymphoma (PCNSL) is a rare and distinct entity within diffuse large B-cell lymphoma presenting with variable response rates probably to underlying molecular heterogeneity.To identify and characterize PCNSL heterogeneity and facilitate clinical translation, we carried out a comprehensive multi-omic analysis [whole-exome sequencing, RNA sequencing (RNA-seq), methylation sequencing, and clinical features] in a discovery cohort of 147 fresh-frozen (FF) immunocompetent PCNSLs and a validation cohort of formalin-fixed, paraffin-embedded (FFPE) 93 PCNSLs with RNA-seq and clinico-radiological data.Consensus clustering of multi-omic data uncovered concordant classification of four robust, non-overlapping, prognostically significant clusters (CS). The CS1 and CS2 groups presented an immune-cold hypermethylated profile but a distinct clinical behavior. The 'immune-hot' CS4 group, enriched with mutations increasing the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) and nuclear factor-κB activity, had the most favorable clinical outcome, while the heterogeneous-immune CS3 group had the worse prognosis probably due to its association with meningeal infiltration and enriched HIST1H1E mutations. CS1 was characterized by high Polycomb repressive complex 2 activity and CDKN2A/B loss leading to higher proliferation activity. Integrated analysis on proposed targets suggests potential use of immune checkpoint inhibitors/JAK1 inhibitors for CS4, cyclin D-Cdk4,6 plus phosphoinositide 3-kinase (PI3K) inhibitors for CS1, lenalidomide/demethylating drugs for CS2, and enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) inhibitors for CS3. We developed an algorithm to identify the PCNSL subtypes using RNA-seq data from either FFPE or FF tissue.The integration of genome-wide data from multi-omic data revealed four molecular patterns in PCNSL with a distinctive prognostic impact that provides a basis for future clinical stratification and subtype-based targeted interventions.

Published
2023

10. CAR‐T CELLS RADICALLY MODIFY THE MANAGEMENT OF RELAPSED/REFRACTORY PRIMARY CEREBRAL LYMPHOMAS. REAL LIFE RESULTS OF THE FRENCH LOC NETWORK

Author

Choquet, S., primary, Soussain, C., additional, Waultier‐Rascalou, A., additional, Xuan, K. Hoang, additional, Guffroy, B., additional, Ahle, G., additional, Barrie, M., additional, Galicier, L., additional, Diblasi, R., additional, Ursu, R., additional, Houot, R., additional, Alcantara, M., additional, Salanouba, C., additional, Willems, L., additional, Gauthier, N., additional, Quoc, S. Nguyen, additional, Metz, C., additional, Uzunov, M., additional, Morel, V., additional, Weil, D. Roos, additional, Souchet, L., additional, Legarff‐Tavernier, M., additional, and Houillier, C., additional

Published
2023
Full Text
View/download PDF

11. A low lymphocyte‐to‐monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trial

Author

Mozas, P., primary, Ammar, R. Ould, additional, Chartier, L., additional, Nastoupil, L., additional, Bachy, E., additional, Bezsera, S. M., additional, Barnes, J., additional, Bijou, F., additional, Goy, A., additional, Zerazhi, H., additional, Cartron, G., additional, Ojeda‐Uribe, M., additional, Choquet, S., additional, Joly, B., additional, Cheminant, M., additional, García‐Sancho, A. Martín, additional, Eradat, H., additional, Gressin, R., additional, Abrisqueta, P., additional, Parcelier, A., additional, Salazar, M. J. Rodríguez, additional, Bonnet, C., additional, Crump, M., additional, López‐Guillermo, A., additional, and Morschhauser, F., additional

Published
2023
Full Text
View/download PDF

12. Outcomes in patients with EBV+ PTLD treated with allogeneic EBV‐specific T‐cell immunotherapy (tabelecleucel) under an expanded access program (EAP) in Europe

Author

Choquet, S., primary, Clark, A., additional, Renard, C., additional, Uttenthal, B., additional, Chaganti, S., additional, Trappe, R. U., additional, Comoli, P., additional, Duan, X., additional, Xing, B., additional, Wu, C., additional, Gamelin, L., additional, Terwey, J., additional, Friedetzky, A., additional, and Dierickx, D., additional

Published
2023
Full Text
View/download PDF

13. AXICABTAGENE CILOLEUCEL AS SECOND‐LINE THERAPY FOR LARGE B‐CELL LYMPHOMA IN TRANSPLANT‐INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY

Author

Houot, R., primary, Bachy, E., additional, Cartron, G., additional, Gros, F., additional, Morschhauser, F., additional, Oberic, L., additional, Gastinne, T., additional, Feugier, P., additional, Dulery, R., additional, Thieblemont, C., additional, Joris, M., additional, Jardin, F., additional, Choquet, S., additional, Casasnovas, O., additional, Brisou, G., additional, Cheminant, M., additional, Bay, J., additional, Gutierrez, F. Llamas, additional, Menard, C., additional, Tarte, K., additional, Delfau, M., additional, Itti, E., additional, Bailly, C., additional, Al Tabaa, Y., additional, Laurent, C., additional, and Lemonnier, F., additional

Published
2023
Full Text
View/download PDF

14. MO-0949 Phase 1 study of escalated total marrow irradiation and melphalan at 1st relapse in multiple myeloma

Author

Cailleteau, A., primary, Maingon, P., additional, Choquet, S., additional, Bourdais, R., additional, Antoni, D., additional, Lioure, B., additional, Hulin, C., additional, Batard, S., additional, Llagostera, C., additional, Guimas, V., additional, Touzeau, C., additional, Moreau, P., additional, Mahé, M., additional, and Supiot, S., additional

Published
2023
Full Text
View/download PDF

16. International Prognostic Index, Type of Transplant and Response to Rituximab Are Key Parameters to Tailor Treatment in Adults With CD20-Positive B Cell PTLD: Clues From the PTLD-1 Trial

Author

Trappe, R.U., Choquet, S., Dierickx, D., Mollee, P., Zaucha, J.M., Dreyling, M.H., Dührsen, U., Tarella, C., Shpilberg, O., Sender, M., Salles, G., Morschhauser, F., Jaccard, A., Lamy, T., Reinke, P., Neuhaus, R., Lehmkuhl, H., Horst, H.A., Leithäuser, M., Schlattmann, P., Anagnostopoulos, I., Raphael, M., Riess, H., Leblond, V., and Oertel, S.

Published
2015
Full Text
View/download PDF

18. High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study

Author

Schorb, E, Fox, C P, Fritsch, K, Isbell, L, Neubauer, A, Tzalavras, A, Witherall, R, Choquet, S, Kuittinen, O, De-Silva, D, Cwynarski, K, Houillier, C, Hoang-Xuan, K, Touitou, V, Cassoux, N, Marolleau, J-P, Tamburini, J, Houot, R, Delwail, V, Illerhaus, G, Soussain, C, and Kasenda, B

Published
2017
Full Text
View/download PDF

19. Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1

Author

Cosson, A, Chapiro, E, Bougacha, N, Lambert, J, Herbi, L, Cung, H-A, Algrin, C, Keren, B, Damm, F, Gabillaud, C, Brunelle-Navas, M-N, Davi, F, Merle-Béral, H, Le Garff-Tavernier, M, Roos-Weil, D, Choquet, S, Uzunov, M, Morel, V, Leblond, V, Maloum, K, Lepretre, S, Feugier, P, Lesty, C, Lejeune, J, Sutton, L, Landesman, Y, Susin, S A, and Nguyen-Khac, F

Published
2017
Full Text
View/download PDF

23. Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC

Author

Tessoulin, B, Ceballos, P, Chevallier, P, Blaise, D, Tournilhac, O, Gauthier, J, Maillard, N, Tabrizi, R, Choquet, S, Carras, S, Ifrah, N, Guillerm, G, Mohty, M, Tilly, H, Socie, G, Cornillon, J, Hermine, O, Daguindau, É, Bachy, E, Girault, S, Marchand, T, Oberic, L, Reman, O, Leux, C, and Le Gouill, S

Published
2016
Full Text
View/download PDF

26. S256: TABELECLEUCEL FOR EBV-DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL OR SOLID ORGAN TRANSPLANT AFTER FAILURE OF RITUXIMAB ± CHEMOTHERAPY (ALLELE)

Author

Prockop, S., primary, Beitinjaneh, A., additional, Choquet, S., additional, Dahiya, S., additional, Dinavahi, R., additional, Farah, R., additional, Gamelin, L., additional, Ghobadi, A., additional, Mehta, A., additional, Nayak, P., additional, Reshef, R., additional, Satyanarayana, G., additional, Stiff, P., additional, Ye, W., additional, and Mahadeo, K. M., additional

Published
2022
Full Text
View/download PDF

27. S210: CAR T-CELLS ASSOCIATED ACUTE TOXICITY IN B-CELL NON-HODGKIN LYMPHOMA: REAL-WORLD STUDY FROM THE DESCAR-T REGISTRY

Author

SESQUES, P., primary, DI BLASI, R., additional, LE GOUILL, S., additional, CARTRON, G., additional, MANSON, G., additional, BEAUVAIS, D., additional, LE BRAS, F., additional, GROS, F. X., additional, CHOQUET, S., additional, BORIES, P., additional, RUBIO, M. T., additional, CASASNOVAS, R. O., additional, BOUNAIX, L., additional, MOHTY, M., additional, JORIS, M., additional, ABRAHAM, J., additional, CASTILLA LLORENTE, C., additional, LOSCHI, M., additional, CARRAS, S., additional, CHAUCHET, A., additional, DRIEU LA ROCHELLE, L., additional, ZERBIT, J., additional, HERMINE, O., additional, GUIDEZ, S., additional, GASTINNE, T., additional, TUDESQ, J. J., additional, FOGARTY, P., additional, BROUSSAIS, F., additional, MORSCHHAUSER, F., additional, HOUOT, R., additional, THIEBLEMONT, C., additional, and BACHY, E., additional

Published
2022
Full Text
View/download PDF

28. S260: A MATCHED COMPARISON OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL CAR T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-LIFE LYSA STUDY FROM THE FRENCH DESCAR-T REGISTRY

Author

Bachy, E., primary, Le Gouill, S., additional, Sesques, P., additional, Di Blasi, R., additional, Guillaume, M., additional, Cartron, G., additional, Beauvais, D., additional, Roulin, L., additional, Gros, F. X., additional, Rubio, M. T., additional, Bories, P., additional, Bay, J. O., additional, Castilla Llorente, C., additional, Choquet, S., additional, Casasnovas, R.-O., additional, Mothy, M., additional, Guidez, S., additional, Joris, M., additional, Loschi, M., additional, Carras, S., additional, Abraham, J., additional, Chauchet, A., additional, Drieu La Rochelle, L., additional, Zerbit, J., additional, Hermine, O., additional, Gastinne, T., additional, Tudesq, J. J., additional, Gat, E., additional, Broussais, F., additional, Thieblemont, C., additional, Houot, R., additional, and Morschhauser, F., additional

Published
2022
Full Text
View/download PDF

29. P1457: DEMOGRAPHICS AND TREATMENT OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH OFF-THE-SHELF EBV-SPECIFIC CTL (TABELECLEUCEL) UNDER AN ONGOING EXPANDED ACCESS PROGRAM IN EUROPE: FIRST ANALYSES

Author

Choquet, S., primary, Uttenthal, B., additional, Chaganti, S., additional, Comoli, P., additional, Trappe, R., additional, Friedetzky, A., additional, Xing, B., additional, Li, X., additional, Polak, T., additional, Gamelin, L., additional, Terwey, J.-H., additional, and Dierickx, D., additional

Published
2022
Full Text
View/download PDF

31. The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study

Author

Zijlstra, JM, Follows, G, Casasnovas, R-O, Vermaat, JSP, Kalakonda, N, Choquet, S, Hill, B, Thieblemont, C, Cavallo, F, Cruz, FDL, Kuruvilla, J, Hamad, N, Jaeger, U, Caimi, P, Gurion, R, Warzocha, K, Bakhshi, S, Sancho, J-M, Schuster, M, Egyed, M, Offner, F, Vassilakopoulos, TP, Samal, P, Ku, M, Xu, J, Corona, K, Chamoun, K, Shah, J, Canales, M, Maerevoet, M, Zijlstra, JM, Follows, G, Casasnovas, R-O, Vermaat, JSP, Kalakonda, N, Choquet, S, Hill, B, Thieblemont, C, Cavallo, F, Cruz, FDL, Kuruvilla, J, Hamad, N, Jaeger, U, Caimi, P, Gurion, R, Warzocha, K, Bakhshi, S, Sancho, J-M, Schuster, M, Egyed, M, Offner, F, Vassilakopoulos, TP, Samal, P, Ku, M, Xu, J, Corona, K, Chamoun, K, Shah, J, Canales, M, and Maerevoet, M

Abstract

Selinexor, an oral selective inhibitor of nuclear export, was evaluated in the Phase 2b SADAL study in patients with diffuse large B-cell lymphoma (DLBCL) who previously received two to five prior systemic regimens. In post hoc analyses, we analyzed several categories of patient characteristics (age, renal function, DLBCL subtype, absolute lymphocyte count, transplant status, number of prior lines of therapy, refractory status, Ann Arbor disease stage, and lactate dehydrogenase) at baseline, i.e., during screening procedures, to determine their potential contributions to the efficacy (overall response rate [ORR], duration of response [DOR], overall survival [OS]) and tolerability of selinexor. Across most categories of characteristics, no significant difference was observed in ORR or DOR. OS was significantly longer for patients < 65 vs. ≥ 65 years, and for those with lymphocyte counts ≥ 1000/µL vs. < 1000/µL or lactate dehydrogenase ≤ ULN vs. > ULN. The most common adverse events (AEs) across the characteristics were thrombocytopenia and nausea, and similar rates of grade 3 AEs and serious AEs were observed. With its oral administration, novel mechanism of action, and consistency in responses in heavily pretreated patients, selinexor may help to address an important unmet clinical need in the treatment of DLBCL.

Published
2022

32. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study

Author

Schuster, M. Zijlstra, J. Casasnovas, R.-O. Vermaat, J.S.P. Kalakonda, N. Goy, A. Choquet, S. Neste, E.V.D. Hill, B. Thieblemont, C. Cavallo, F. De la Cruz, F. Kuruvilla, J. Hamad, N. Jaeger, U. Caimi, P. Gurion, R. Warzocha, K. Bakhshi, S. Sancho, J.-M. Follows, G. Egyed, M. Offner, F. Vassilakopoulos, T. Samal, P. Ku, M. Ma, X. Corona, K. Chamoun, K. Shah, J. Shacham, S. Kauffman, M.G. Canales, M. Maerevoet, M.

Abstract

Background: Despite a number of treatment options, patients with diffuse large B-cell lymphoma (DLBCL) whose disease has become refractory to treatment have a poor prognosis. Selinexor is a novel, oral drug that is approved to treat patients with relapsed/refractory DLBCL. In this post hoc analysis of the SADAL study, a multinational, open-label study, we evaluated subpopulations to determine if response to single agent selinexor is impacted by number of lines of prior treatment, autologous stem cell transplant (ASCT), response to first and most recent therapies, and time to progressive disease. Patients: Patients (n = 134) with DLBCL after 2-5 prior therapies were enrolled in SADAL and received 60mg selinexor twice weekly. Results: The median overall survival was 9.0 months and median progression free survival was 2.6 months. Patients who had the best overall response rate (ORR) and disease control rate were those who had prior ASCT (42.5% and 50.0%) or responded to last line of therapy (35.9% and 43.5%). Patients with primary refractory DLBCL also showed responses (ORR 21.8%). Adverse events between subgroups were similar to the overall study population, the most common being thrombocytopenia (29.1%), fatigue (7.5%), and nausea (6.0%). Conclusion: Regardless of prior therapy and disease refractory status, selinexor treatment demonstrated results consistent with its novel mechanism of action and lack of cross-resistance. Thus, single agent oral selinexor can induce deep, durable, and tolerable responses in patients with DLBCL who have recurrent disease after several chemoimmunotherapy combination regimens. © 2021

Published
2022

39. Transfusion needs after CD19 CAR T‐cells for large B‐cell lymphoma: predictive factors and impact on outcome. A DESCAR‐T study.

Author

Vic, S., Thibert, J., Bachy, E., Cartron, G., Gastinne, T., Morschhauser, F., Le Bras, F., Bouabdallah, K., Despas, F., Bay, J., Rubio, M., Mohty, M., Casasnovas, O., Choquet, S., Castilla‐Llorente, C., Guidez, S., Loschi, M., Guffroy, B., Carras, S., and La Rochelle, L. Drieu

Subjects
T cells, CD19 antigen, ERYTHROCYTES, LYMPHOMAS, CYTOKINE release syndrome
Abstract

Transfusion needs may impact patients' quality of life and CAR T-cells efficacy through transfusion-related immunomodulation. Transfusion needs after CD19 CAR T-cells for large B-cell lymphoma: predictive factors and impact on outcome. B Introduction: b Patients undergoing CAR T-cell therapy may experience severe cytopenias due to lymphodepleting chemotherapy and/or CAR T-cells. [Extracted from the article]

Published
2023
Full Text
View/download PDF

40. PROGNOSTIC SCORING SYSTEMS FOR SEVERE CRS AND ICANS AFTER AUTOLOGOUS ANTI‐CD19 CAR T CELLS IN LARGE B‐CELL LYMPHOMA: A DESCAR‐T REGISTRY STUDY FORM THE LYSA.

Author

Sesques, P., Di blasi, R., Legouill, S., Cartron, G., Beauvais, D., Le Bras, F., Gros, F., Choquet, S., Bories, P., Rubio, M., Casasnovas, R., Bay, J., Mohty, M., Joris, M., Abraham, J., Llorente, C. Castilla, Loschi, M., Carras, S., Chauchet, A., and Gyan, E.

Subjects
T cells, CYTOKINE release syndrome, LYMPHOMAS
Abstract

PROGNOSTIC SCORING SYSTEMS FOR SEVERE CRS AND ICANS AFTER AUTOLOGOUS ANTI-CD19 CAR T CELLS IN LARGE B-CELL LYMPHOMA: A DESCAR-T REGISTRY STUDY FORM THE LYSA B Background: b Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are common immune-related toxicities associated with chimeric antigen receptor (CAR)-T-cell therapy. B S. Legouill b Honoraria: Janssen-Cilag, Kite/Gilead and Novartis B G. Cartron b Honoraria: Roche, Bristol Myers Squibb, Onwards Therapeutics, MedxCell, EmerCell, MabQ, Sanofi, Abbvie, Takeda, Roche, Janssen, Roche, Novartis and Myltenyi B D. Beauvais b Honoraria: Kite/Gilead B F. Gros b Honoraria: Bristol Myers Squibb, Novartis and Kite/Gilead B P. Bories b Honoraria: Bristol Myers Squibb, Kite/Gilead, Novartis and Abbvie B M. Rubio b Honoraria: Novartis and Kite/Gilead. [Extracted from the article]

Published
2023
Full Text
View/download PDF

42. FIRST RESULTS OF DLBCL PATIENTS TREATED WITH CAR‐T CELLS AND ENROLLED IN DESCAR‐T REGISTRY, A FRENCH REAL‐LIFE DATABASE FOR CAR‐T CELLS IN HEMATOLOGIC MALIGNANCIES

Author

Gouill, S., primary, Bachy, E., additional, Blasi, R., additional, Cartron, G., additional, Beauvais, D., additional, Bras, F., additional, Gros, François‐X., additional, Choquet, S., additional, Bories, P., additional, Rubio, Marie‐Thérès., additional, Casasnovas, René‐O., additional, Bounaix, L., additional, Mohty, M., additional, Joris, M., additional, Gastinne, T., additional, Sesques, P., additional, Tudesq, J. J., additional, Morschhauser, F., additional, Gat, E., additional, Broussais, F., additional, Thieblemont, C., additional, and Houot, R., additional

Published
2021
Full Text
View/download PDF

44. OUTCOMES AFTER FIRST‐LINE IMMUNOCHEMOTHERAPY FOR PRIMARY MEDIASTINAL B CELL LYMPHOMA PATIENTS: A LYSA STUDY

Author

Camus, V., primary, Rossi, C., additional, Sesques, P., additional, Lequesne, J., additional, Tonnelet, D., additional, Haioun, C., additional, Durot, E., additional, Willaume, A., additional, Gauthier, M., additional, Moles‐Moreau, Marie‐P., additional, Antier, C., additional, Lazarovici, J., additional, Monjanel, H., additional, Bernard, S., additional, Tardy, M., additional, Besson, C., additional, Lebras, L., additional, Choquet, S., additional, Le Du, K., additional, Bonnet, C., additional, Bailly, S., additional, Damaj, G.‐L., additional, Laribi, K., additional, Maisonneuve, H., additional, Houot, R., additional, Chauchet, A., additional, Jardin, F., additional, Traverse‐Glehen, A., additional, Decazes, P., additional, Becker, S., additional, Berriolo‐Riedinger, A., additional, and Tilly, H., additional

Published
2021
Full Text
View/download PDF

45. CAR‐T CELL THERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL): THE EXPERIENCE OF THE FRENCH NETWORK FOR OCULO‐CEREBRAL LYMPHOMAS (LOC)

Author

Alcantara, M., primary, Houillier, C., additional, Garff‐Tavernier, M., additional, Souchet, L., additional, Roos‐Weil, D., additional, Morel, V., additional, Uzunov, M., additional, Metz, C., additional, Nguyen‐Quoc, S., additional, Jacque, N., additional, Gauthier, N., additional, Cann, M., additional, Norol, F., additional, Willems, L., additional, Waultier Rascalou, A., additional, Salanoubat, C., additional, Fior, R., additional, Blonski, M., additional, Rubio, M.‐T., additional, Soussain, C., additional, and Choquet, S., additional

Published
2021
Full Text
View/download PDF

47. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

Author

Shah, J., Shacham, S., Kauffman, M., Daniele, P., Tomaras, D., Tremblay, G., Casasnovas, R.O., Maerevoet, M., Zijlstra, J., Follows, G., Vermaat, J.S.P., Kalakonda, N., Goy, A.H., Choquet, S., Neste, E. van den, Hill, B.T., Thieblemont, C., Cavallo, F., Cruz, F. de la, Kuruvilla, J., Hamad, N., Bouabdallah, R., Jager, U., Caimi, P., Gurion, R., Warzocha, K., Bakhshi, S., Sancho, J.M., Schuster, M., Egyed, M., Offner, F., Vasilakopoulos, T.P., Samal, P., Nagy, A., Ku, M., and Albendea, M.A.C.

Subjects
health-related quality of life, disutility of adverse events, EQ-5D-5L, diffuse large B-cell lymphoma, health utility, FACT-Lym, patient reported outcomes, health state utility, selinexor
Abstract

Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therapy (FACT) - Lymphoma and EuroQoL five-dimensions five-levels data collected in the single-arm Phase IIb trial SADAL (NCT02227251) were analyzed with mixed-effects models. Results: Treatment responders maintained higher FACT - Lymphoma (p = 3 adverse events and serious adverse events were not associated with clinically meaningful negative QoL impacts.

Published
2021

48. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

Author

Shah, J. Shacham, S. Kauffman, M. Daniele, P. Tomaras, D. Tremblay, G. Casasnovas, R.-O. Maerevoet, M. Zijlstra, J. Follows, G. P Vermaat, J.S. Kalakonda, N. Goy, A.H. Choquet, S. Den Neste, E.V. Hill, B.T. Thieblemont, C. Cavallo, F. La Cruz, F.D. Kuruvilla, J. Hamad, N. Bouabdallah, R. Jäger, U. Caimi, P. Gurion, R. Warzocha, K. Bakhshi, S. Sancho, J.M. Schuster, M. Egyed, M. Offner, F. Vasilakopoulos, T.P. Samal, P. Nagy, A. Ku, M. Canales Albendea, M.Á.

Abstract

Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therapy (FACT)-Lymphoma and EuroQoL five-dimensions five-levels data collected in the single-arm Phase IIb trial SADAL (NCT02227251) were analyzed with mixed-effects models. Results: Treatment responders maintained higher FACT-Lymphoma (p ≤ 0.05), FACT-General (p < 0.05) and EuroQoL five-dimensions five-levels index scores (p < 0.001) beginning in cycle 3. The estimated difference in health state utilities for treatment response and progressive disease was both statistically significant and clinically meaningful (mean difference: 0.07; p = 0.001). Conclusion: In patients with relapsed/refractory diffuse large B-cell lymphoma, objective response to selinexor was associated with HRQoL maintenance, reduction in disease-related HRQoL decrements and higher health utilities. © 2021 Patrick Daniele.

Published
2021

49. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

Author

Shah, J, Shacham, S, Kauffman, M, Daniele, P, Tomaras, D, Tremblay, G, Casasnovas, RO, Maerevoet, M, Zijlstra, J, Follows, G, Vermaat, JSP, Kalakonda, N, Goy, AH, Choquet, S, Van den Neste, E, Hill, BT, Thieblemont, C, Cavallo, F, de la Cruz, F, Kuruvilla, J, Hamad, N, Bouabdallah, R, Jager, U, Caimi, P, Gurion, R, Warzocha, K, Bakhshi, S, Sancho, JM, Schuster, M, Egyed, M, Offner, F, Vasilakopoulos, TP, Samal, P, Nagy, A, Ku, M, and Albendea, MAC

Subjects
health-related quality of life, disutility of adverse events, EQ-5D-5L, diffuse large B-cell lymphoma, health utility, FACT-Lym, patient reported outcomes, health state utility, selinexor
Abstract

Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therapy (FACT) - Lymphoma and EuroQoL five-dimensions five-levels data collected in the single-arm Phase IIb trial SADAL (NCT02227251) were analyzed with mixed-effects models. Results: Treatment responders maintained higher FACT - Lymphoma (p = 3 adverse events and serious adverse events were not associated with clinically meaningful negative QoL impacts.

Published
2021

50. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study

Author

Maerevoet, M, Zijlstra, JM, Follows, G, Casasnovas, R-O, Vermaat, JSP, Kalakonda, N, Goy, A, Choquet, S, Van den Neste, E, Hill, B, Thieblemont, C, Cavallo, F, De la Cruz, F, Kuruvilla, J, Hamad, N, Jaeger, U, Caimi, P, Gurion, R, Warzocha, K, Bakhshi, S, Sancho, J-M, Schuster, M, Egyed, M, Offner, F, Vassilakopoulos, TP, Samal, P, Ku, M, Ma, X, Corona, K, Chamoun, K, Shah, J, Shacham, S, Kauffman, MG, Canales, M, Maerevoet, M, Zijlstra, JM, Follows, G, Casasnovas, R-O, Vermaat, JSP, Kalakonda, N, Goy, A, Choquet, S, Van den Neste, E, Hill, B, Thieblemont, C, Cavallo, F, De la Cruz, F, Kuruvilla, J, Hamad, N, Jaeger, U, Caimi, P, Gurion, R, Warzocha, K, Bakhshi, S, Sancho, J-M, Schuster, M, Egyed, M, Offner, F, Vassilakopoulos, TP, Samal, P, Ku, M, Ma, X, Corona, K, Chamoun, K, Shah, J, Shacham, S, Kauffman, MG, and Canales, M

Abstract

Patients with RR DLBCL who have received ≥ 2 lines of therapy have limited treatment options and an expected overall survival (OS) of < 6 months. The SADAL study evaluated single-agent oral selinexor in patients with RR DLBCL and demonstrated an overall response rate (ORR) of 29.1% with median duration of response (DOR) of 9.3 months. The analyses described here evaluated a number of subpopulations in order to understand how response correlates with survival outcomes in order to identify patients who could most optimally benefit from selinexor treatment. Median age was 67 years; 44.8% of patients were ≥ 70 years of age. The median OS was 9.0 months (95% CI 6.2, 13.7) at a median follow-up of 14.8 months. The median OS was not reached in patients with a CR or PR, while patients who did not respond have a median OS of 4.9 months (p < 0.0001). Patients < 70 years had an OS of 11.1 months compared with 7.8 months in patients ≥ 70 years. Among patients with or without prior ASCT, the median OS was 10.9 and 7.8 months, respectively. Among patients with disease refractory to the most recent DLBCL treatment regimen, the median OS was 7.0 months compared with 11.1 months for disease not refractory to the most recent treatment. In a patient population in which survival is expected to be < 6 months, treatment with single-agent oral selinexor was associated with a median survival of 9 months. Increased median OS observed in patients responding to selinexor was consistent across subgroups regardless of age, prior ASCT therapy, or refractory status. Randomized studies of selinexor in combination with a variety of other anti-DLBCL agents are planned. This trial was registered at ClinicalTrials.gov (NCT02227251) on August 28, 2014. https://clinicaltrials.gov/ct2/show/NCT02227251 .

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results